Home >> People >> Faculty
WANG Yuexiang

Ph.D.

Professor, Principal Investigator

Laboratory of Cancer Progression and Translational Medicine

Email: yxwang76@sibs.ac.cn

Tel: 86-21-54923278

Research Areas:

Cancer is a genetic disease caused by the accumulation of genomic alterations. Our laboratory is interested in discovering genomic events that cause human cancers. We are aiming to translate these findings into early diagnosis and treatments for these deadly diseases. Our laboratory is engaged in:

(1) Molecular mechanisms of sarcoma progression;

(2) Molecular mechanisms of non-sarcoma cancer progression;

(3) Pan-cancer genomic analysis;

(4) Development of novel diagnostic tools and novel anti-cancer drugs.

 

Brief Biography:

Education

1994.9-1999.7: Bachelor’s Degree in Medical Sciences, Shanghai Medical University 

2001.9-2007.1: Ph.D. Degree in Biochemistry and Molecular Biology, Fudan University  

Major Academic Appointments 

2017-present: Professor, Principal Investigator, Shanghai Institute of Nutrition and Health, CAS 

2015-2016: Professor, Principal Investigator, Shanghai Institutes for Biological Sciences/Joint Center for Translational Medicine (SIBS - Shanghai Changzheng Hospital), Institute for Translational Medicine (CAS-SMMU), Shanghai, China 

2007-2015: Postdoctoral Research Associate/Senior Research Staff Scientist/Instructor, Brigham and Women’s Hospital / Harvard Medical School 

1999-2007: Teaching and Research Assistant/Lecturer/Associate Professor, Shanghai Medical School, Fudan University 

 

Selected Publications: (*Corresponding Author)

Pang Y#, Xie F#, Cao H#, Wang C#, Zhu M, Lu X, Huang T, Shen Y, Liu X, Li K, Jia X, Li Z, Zheng X, Wang S, He Y, Wang L, Fletcher J*, Wang Y*. Mutational inactivation of mTORC1 repressor gene DEPDC5 in human gastrointestinal stromal tumors. Proc Natl Acad Sci U S A 2019 Oct 21. doi: 10.1073/pnas.1914542116.

Li Z#, Shao C#, Liu X, Lu X, Jia X, Zheng X, Wang S, Zhu L, Li K, Pang Y, Xie F, Lu Y, Wang Y*. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. Carcinogenesis 2019 May 2. doi: 10.1093/carcin/bgz086.

Wang YX, Marino-Enriquez A, Bennett RR, Zhu MJ, Shen YP, Eilers G, Lee JC, Fletcher BS, Gu ZZ, Fox EA, Antonescu CR, Fletcher CDM, Guo XQ, Raut CP, Demetri GD, van de Rijn M, Ordog T, Kunkel LM, Fletcher JA. Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nature Genetics (IF: 31.616) 2014;46(6):601-606. (highlighted by “Laboratory Investigation”, “Modern Pathology” and “BioWorld Today”, featured in “Cancer Discovery” Research Watch and selected as one of the most popular stories on nature.com)

Serrano C#, Wang YX#, Marino-Enriquez A, Lee JC, Ravegnini G, Morgan JA, Bertagnolli MM, Beadling C, Demetri GD, Corless CL, Heinrich MC, Fletcher JA. KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GIST: Relevance of concomitant PI3K/AKT dysregulation. Journal of Clinical Oncology (IF: 24.008) 2015;33(22):e93-96. (# Both authors contributed equally)

Wang YX*, Fletcher JA*. Cell cycle and dystrophin dysregulation in GIST. Cell Cycle 2015;14(17):2713-2714.

Li K#, Cheng HB#, Li Z, Pang YZ, Jia XN, Xie FF, Hu GH, Cai QP*, Wang YX*. Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions. Oncotarget 2017;8(36):60589-60604.

Wei ZR#, Liang C#, Feng D#, Cheng YJ, Wang WM, Yang DJ, Wang YX*, Cai QP*. Low tristetraprolin expression promotes cell proliferation and predicts poor patients outcome in pancreatic cancer. Oncotarget 2016;7(14):17737-17750.

Heinrich M, Patterson J, Beadling C, Wang Y, Debiec-Rychter M, Dewaele B, Corless CL, Duensing A, Raut CP, Rubin B, Ordog T, van de Rijn M, Call J, Mühlenberg T, Fletcher JA, Bauer S. Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors. Clinical Sarcoma Research 2019 Mar 5;9:3. doi:10.1186/s13569-019-0112-7. eCollection 2019.

Schaefer IM, Wang Y, Liang CW, Bahri N, Quattrone A, Doyle L, Marino-Enriquez A, Lauria A, Zhu M, Debiec-Rychter M, Grunewald S, Hechtman JF, Dufresne A, Antonescu CR, Beadling C, Sicinska ET, van de Rijn M, Demetri GD, Ladanyi M, Corless CL, Heinrich MC, Raut CP, Bauer S, Fletcher JA. MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nature Communications 2017;8:14674. doi: 10.1038/ncomms14674.

Chen W, Kuang Y, Qiu HB, Cao Z, Tu Y, Sheng Q, Eilers G, He Q, Li HL, Zhu M, Wang Y, Zhang R, Wu Y, Meng F, Fletcher JA, Ou WB. Dual targeting of Insulin Receptor and KIT in imatinib-resistant gastrointestinal stromal tumors. Cancer Research 2017;77(18):5107-5117.

Wang Q, Liu F, Wang B, Zou F, Chen C, Liu X, Wang A, Qi S, Wang W, Qi Z, Zhao Z, Hu Z, Wang W, Wang L, Zhang S, Wang Y, Liu J, Liu Q. Discovery of N-(3-((1- Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide(CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors. Journal of Medicinal Chemistry 2016;59(8):3964-3979.

Maynard MA, Marino-Enriquez A, Fletcher JA, Dorfman DM, Raut CP, Yassa L, Guo C, Wang Y, Dorfman C, Feldman HA, Frates MC, Song H, Jugo RH, Taguchi T, Hershman JM, Larsen PR, Huang SA. Thyroid hormone inactivation in gastrointestinal stromal tumors. New England Journal of Medicine 2014;370(14):1327-1334.

Marino-Enriquez A, Ou WB, Cowley G, Luo B, Jonker AH, Mayeda M, Okamoto M, Eilers G, Czaplinski JT, Sicinska E, Wang Y, Taguchi T, Demetri GD, Root DE, Fletcher JA. Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors. Oncogene 2014;33(14):1872-1876.

Lynn M, Wang Y, Slater J, Shah N, Conroy J, Ennis S, Morris T, Betts DR, Fletcher JA, O'Sullivan MJ. High-resolution genome-wide copy-number analyses identify localized copy-number alterations in Ewing sarcoma. Diagnostic Molecular Pathology 2013;22(2):76-84.

Ravegnini G, Marino-Enriquez A, Slater J, Eilers G, Wang Y, Zhu M, Nucci MR,George S, Angelini S, Raut CP, Fletcher JA. MED12 mutations in leiomyosarcoma and extrauterine leiomyoma. Modern Pathology 2013;26(5):743-749.

Lee CH, Ou WB, Marino-Enriquez A, Zhu M, Mayeda M, Wang Y, Guo X, Brunner AL, Amant F, French CA, West RB, McAlpine JN, Gilks CB, Yaffe MB, Prentice LM,McPherson A, Jones SJ, Marra MA, Shah SP, van de Rijn M, Huntsman DG, Dal Cin P, Debiec-Rychter M, Nucci MR, Fletcher JA. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A 2012;109(3):929-934.

Wang YX, Qian LX, Dong YX, Yao LL, Gui YH, Zhong TP, Song HY. Bone Morphogenetic Protein-2 acts upstream of Myocyte-specific Enhancer Factor 2A to control embryonic cardiac contractility. Cardiovascular Research 2007;74(2):290-303.

Wang YX, Qian LX, Jiang Q, Dong YX, Gui YH, Zhong TP, Song HY. Myocyte-specific enhancer factor 2A is essential for zebrafish posterior somite development. Mechanisms of Development 2006;123(10):783-791.

Wang YX, Qian LX, Yu Z, Jiang Q, Dong YX, Liu XF, Yang XY, Zhong TP, Song HY. Requirements of myocyte-specific enhancer factor 2A in zebrafish cardiac contractility. FEBS Letters 2005;579(21):4843-4850.

Wang Y, Zhong T, Qian L, Dong Y, Jiang Q, Tan L, Song H. Wortmannin induces zebrafish cardia bifida through a mechanism independent of phosphoinositide 3-kinase and myosin light chain kinase. Biochemical and Biophysical Research Communications 2005;331(1):303-308 (Cover Photo).

Wang YX, Song HY. Developmental genetics of zebrafish cardiovascular systems. Foreign Medical Sciences (Section of Genetics) 2004;27(4):220-223.

Wang YX, Yang J, Ma CG, Yang XY, Song HY. VEGF121 cDNA gene transfer and expression in Vitro. Progress in Biochemistry and Biophysics 2003;30(4):612-616.

Wang YX, Guan XQ, Yang J, Mo W, Song HY. Molecular Cloning, Expression and characterization of recombinant human vascular endothelial growth factor 121. Progress in Biochemistry and Biophysics 2002;29(3):444-448.